Connor, Clark & Lunn Investment Management (CC&L)
STRO icon

Connor, Clark & Lunn Investment Management (CC&L)’s Sutro Biopharma STRO Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-32,632
Closed -$600K – 1593
2024
Q4 		$600K Sell
32,632
-11,073
-25% -$338K ﹤0.01% 1095
2024
Q3 		$1.51M Buy
+43,705
New +$1.71M 0.01% 747
2023
Q1 		– Sell
-6,523
Closed -$527K – 1442
2022
Q4 		$527K Buy
6,523
+586
+10% +$40.7K ﹤0.01% 847
2022
Q3 		$330K Buy
5,937
+3,344
+129% +$198K ﹤0.01% 900
2022
Q2 		$135K Buy
+2,593
New +$145K ﹤0.01% 968
2022
Q1 		– Sell
-2,189
Closed -$326K – 1207
2021
Q4 		$326K Sell
2,189
-1,652
-43% -$296K ﹤0.01% 879
2021
Q3 		$726K Buy
3,841
+1,469
+62% +$279K ﹤0.01% 701
2021
Q2 		$441K Buy
2,372
+926
+64% +$181K ﹤0.01% 809
2021
Q1 		$329K Buy
1,446
+334
+30% +$79.3K ﹤0.01% 851
2020
Q4 		$241K Buy
+1,112
New +$184K ﹤0.01% 813

Other funds holding STRO

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s STRO Position: Q1 2025 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Sutro Biopharma (STRO) in Q1 2025, closing a stake of 32,632 shares — an estimated $600K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in STRO in Q4 2020 and held it in 10 quarters. The position peaked at $1.51M in Q3 2024. 112 funds tracked by Wall St. Rank hold STRO as of Q1 2025.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Sutro Biopharma position as of Q1 2025 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 32,632 Sutro Biopharma shares in Q1 2025, an estimated $600K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Sutro Biopharma in Q4 2020 and held it in 10 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Sutro Biopharma position peaked at $1.51M in Q3 2024.
  • 112 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2025.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2025, filed 12 May 2025.